

# James R Cook

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7399302/publications.pdf>

Version: 2024-02-01

66  
papers

1,528  
citations

448610

19  
h-index

388640

36  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinically Significant <i>CLUX1</i> Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. <i>American Journal of Clinical Pathology</i> , 2022, 157, 586-594.	0.4	1
2	<i>IRTA1</i> positivity helps identify a MALT lymphoma-like subset of primary cutaneous marginal zone lymphomas, largely but not exclusively defined by <i>IgM</i> expression. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 55-60.	0.7	11
3	Designing Myeloid Gene Panels. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1004-1011.	1.2	1
4	Myeloid Sarcoma Involving the Testis in Adults. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, Publish Ahead of Print, .	0.6	0
5	A Model for Design and Implementation of a Laboratory Information-Management System Specific for Molecular Pathology Laboratory Operations. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 503-514.	1.2	1
6	Ultrasensitive RNA In Situ Hybridization for Kappa and Lambda Light Chains Assists in the Differential Diagnosis of Nodular Lymphocyte-predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1078-1083.	2.1	1
7	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
8	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	0.8	17
9	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas. <i>Cancer Genetics</i> , 2021, 252-253, 43-47.	0.2	0
10	Novel invariant features of Good syndrome. <i>Leukemia</i> , 2021, 35, 1792-1796.	3.3	11
11	Clinical and Pathologic Spectrum of <i>DDX41</i> -Mutated Hematolymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2021, 156, 829-838.	0.4	15
12	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6039-6053.	3.2	17
13	Impact of next generation sequencing results on clinical management in patients with hematological disorders. <i>Leukemia and Lymphoma</i> , 2021, 62, 1702-1710.	0.6	4
14	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	0.6	1
15	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4479-4479.	0.6	0
16	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021, 138, 1326-1326.	0.6	1
17	Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML. <i>Blood</i> , 2021, 138, 1295-1295.	0.6	0
18	Myeloid neoplasm with eosinophilia and <i>ETV6-JAK2</i> fusion. <i>Leukemia and Lymphoma</i> , 2020, 61, 213-216.	0.6	3

#	ARTICLE	IF	CITATIONS
19	As the world turns, evolving lymphoma classificationsâ€œpast, present and future. <i>Human Pathology</i> , 2020, 95, 55-77.	1.1	22
20	Primary effusion lymphoma in human immune deficiency (HIV)â€œnegative nonâ€œorgan transplant immunocompetent patients. <i>Diagnostic Cytopathology</i> , 2020, 48, 380-385.	0.5	8
21	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma. <i>Human Pathology</i> , 2020, 106, 93-105.	1.1	27
22	Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. <i>American Journal of Clinical Pathology</i> , 2020, 154, 124-132.	0.4	11
23	Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e86-e88.	0.7	4
24	Molecular and Cytogenetic Education in Hematopathology Fellowship. <i>American Journal of Clinical Pathology</i> , 2019, 152, 438-445.	0.4	3
25	Comparison of realâ€œtime PCR vs PCR with fragment length analysis for the detection of <i>CD22</i> mutations in suspected myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e139-e141.	0.7	2
26	Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1403-1412.	2.1	31
27	IRTA1 and MNDA Expression in Marginal Zone Lymphoma. <i>American Journal of Clinical Pathology</i> , 2019, 151, 337-343.	0.4	31
28	Identification of â€œDouble Hitâ€œLymphomas Using Updated WHO Criteria: Insights From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive B-Cell Lymphomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 410-415.	0.6	9
29	Survival Outcomes in Patients with WaldenstrÃ¶m Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. <i>Blood</i> , 2019, 134, 5248-5248.	0.6	1
30	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
31	<i>CD22</i> RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 564-566.	1.2	8
32	Ultrasensitive automated RNA in situ hybridization for kappa and lambda light chain mRNA detects B-cell clonality in tissue biopsies with performance comparable or superior to flow cytometry. <i>Modern Pathology</i> , 2018, 31, 385-394.	2.9	20
33	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
34	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. <i>Blood</i> , 2018, 132, 2270-2270.	0.6	0
35	Design, Validation, and Clinical Implementation of a Gap-Polymerase Chain Reaction Method for $\alpha$ -Thalassemia Genotyping Using Capillary Electrophoresis. <i>Hemoglobin</i> , 2017, 41, 124-130.	0.4	8
36	What Is the Clinical Utility of Repeat SNP Array Testing in the Follow-up of Myeloid Neoplasms?. <i>American Journal of Clinical Pathology</i> , 2017, 147, 278-284.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Anaplastic lymphoma kinase positive large B-cell lymphoma: Literature review and report of an endoscopic fine needle aspiration case with tigroid backgrounds mimicking seminoma. <i>Diagnostic Cytopathology</i> , 2017, 45, 148-155.	0.5	8
38	Outcomes of MYC-associated lymphomas after CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	1.2	27
39	Langerhans cell histiocytosis shows distinct cytoplasmic expression of major histocompatibility class II antigens. <i>Journal of Hematopathology</i> , 2016, 9, 107-112.	0.2	9
40	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
41	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	0.6	0
42	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
43	Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2015, 144, 87-93.	0.4	21
44	MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. <i>Modern Pathology</i> , 2015, 28, 564-574.	2.9	59
45	Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication. <i>Cancer Genetics</i> , 2014, 207, 306-315.	0.2	9
46	Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. <i>Journal of Clinical Pathology</i> , 2014, 67, 1093-1098.	1.0	8
47	Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas. <i>Diagnostic Pathology</i> , 2014, 9, 144.	0.9	21
48	Clinical Significance of MYC Expression and/or High-grade Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 494-501.	2.1	43
49	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	1.1	34
50	Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma. <i>Haematologica</i> , 2014, 99, e154-e155.	1.7	8
51	Nodal and leukemic small B-cell neoplasms. <i>Modern Pathology</i> , 2013, 26, S15-S28.	2.9	9
52	MYD88 L265P Somatic Mutation. <i>American Journal of Clinical Pathology</i> , 2013, 140, 387-394.	0.4	52
53	Immunoarchitectural Patterns of Germinal Center Antigens Including LMO2 Assist in the Differential Diagnosis of Marginal Zone Lymphoma vs Follicular Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 140, 149-154.	0.4	14
54	Ultrasensitive RNA In Situ Hybridization for Detection of Restricted Clonal Expression of Low-Abundance Immunoglobulin Light Chain mRNA in B-Cell Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2013, 140, 736-746.	0.4	35

#	ARTICLE	IF	CITATIONS
55	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue – An L.L.M.P.P. Project. <i>Blood</i> , 2013, 122, 73-73.	0.6	0
56	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 679-679.	0.6	2
57	MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study. <i>Blood</i> , 2012, 120, 543-543.	0.6	1
58	Detection of Copy Number Alterations in DNA Repair/Repair-Related Genes for a Diversity of Hematologic Malignancies Identifies Disease-Specific Biomarkers of Potential Clinical Relevance.. <i>Blood</i> , 2012, 120, 2531-2531.	0.6	0
59	Marginal Zone Lymphomas With Plasmacytic Differentiation and Related Disorders. <i>American Journal of Clinical Pathology</i> , 2011, 136, 211-225.	0.4	76
60	Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: Comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone. <i>Leukemia Research</i> , 2010, 34, 340-343.	0.4	4
61	Splenic B-Cell Lymphomas/Leukemias. <i>Surgical Pathology Clinics</i> , 2010, 3, 933-954.	0.7	3
62	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
63	Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. <i>Human Pathology</i> , 2009, 40, 405-412.	1.1	11
64	Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 459-465.	1.2	23
65	t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 286-292.	0.7	32
66	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle. <i>Leukemia and Lymphoma</i> , 2005, 46, 1423-1427.	0.6	32